BACKGROUND: Patients with bone metastases secondary to breast cancer are pre-disposed to skeletal-related events (SREs), including spinal cord compression (SCC), pathologic fracture (PF), surgery to bone (SB), and radiotherapy to bone (RT). OBJECTIVE: To document current patterns of healthcare utilization and costs of SREs in patients with breast cancer and bone metastases. METHODS: This was a retrospective, observational study using the Thomson MedStat MarketScan Commercial Claims and Encounters database from 9/2002 to 6/2011. Study subjects included all persons with claims for breast cancer and for bone metastases, and ≥1 claims for an SRE. Unique SRE episodes were identified based on a gap of at least 90 days without an SRE claim, and classified by treatment setting (inpatient or outpatient) and SRE type (SCC, PF, SB, or RT). RESULTS: Of 17,266 patients with breast cancer and bone metastases, 9142 (53%) had one or more SRE episodes. Among 5809 patients who met all other criteria, there were 7617 SRE episodes over mean (SD) follow-up of 17.2 (15.2) months. The percentage of episodes that required inpatient treatment ranged from 11% (RT) to 76% (SB). On average, inpatient SCC episodes (n=83 episodes) were most costly; while outpatient PF episodes (n=552 episodes) were least costly. Of the total SRE costs (mean [SE] $21,072 [$36,462]/episode), 36% were attributable to outpatient RT (n=5265 episodes) and 31% to inpatient PF (n=838 episodes). LIMITATIONS: The administrative claims data used in this study may lack sensitivity and specificity for identification of clinical events and may not be generalizable to other populations. Also, for some SRE episode categories, the number of events was small and cost estimates may lack precision. CONCLUSION: In patients with breast cancer and bone metastases, SREs are associated with high costs and hospitalizations.
BACKGROUND:Patients with bone metastases secondary to breast cancer are pre-disposed to skeletal-related events (SREs), including spinal cord compression (SCC), pathologic fracture (PF), surgery to bone (SB), and radiotherapy to bone (RT). OBJECTIVE: To document current patterns of healthcare utilization and costs of SREs in patients with breast cancer and bone metastases. METHODS: This was a retrospective, observational study using the Thomson MedStat MarketScan Commercial Claims and Encounters database from 9/2002 to 6/2011. Study subjects included all persons with claims for breast cancer and for bone metastases, and ≥1 claims for an SRE. Unique SRE episodes were identified based on a gap of at least 90 days without an SRE claim, and classified by treatment setting (inpatient or outpatient) and SRE type (SCC, PF, SB, or RT). RESULTS: Of 17,266 patients with breast cancer and bone metastases, 9142 (53%) had one or more SRE episodes. Among 5809 patients who met all other criteria, there were 7617 SRE episodes over mean (SD) follow-up of 17.2 (15.2) months. The percentage of episodes that required inpatient treatment ranged from 11% (RT) to 76% (SB). On average, inpatient SCC episodes (n=83 episodes) were most costly; while outpatient PF episodes (n=552 episodes) were least costly. Of the total SRE costs (mean [SE] $21,072 [$36,462]/episode), 36% were attributable to outpatient RT (n=5265 episodes) and 31% to inpatient PF (n=838 episodes). LIMITATIONS: The administrative claims data used in this study may lack sensitivity and specificity for identification of clinical events and may not be generalizable to other populations. Also, for some SRE episode categories, the number of events was small and cost estimates may lack precision. CONCLUSION: In patients with breast cancer and bone metastases, SREs are associated with high costs and hospitalizations.
Authors: Suying Li; Haifeng Guo; Yi Peng; Tingting Gong; Alan Fu; Debajyoti Bhowmik; Rohini K Hernandez; Katherine B Carlson; Kimberly A Lowe; Jitesh Rana; Shuling Li Journal: J Bone Oncol Date: 2020-10-21 Impact factor: 4.072
Authors: Jaime M Preussler; Lih-Wen Mau; Navneet S Majhail; Christa L Meyer; Ellen M Denzen; Kristen C Edsall; Stephanie H Farnia; Alicia Silver; Wael Saber; Linda J Burns; David J Vanness Journal: Biol Blood Marrow Transplant Date: 2016-05-14 Impact factor: 5.742
Authors: Arif Hussain; Candice Yong; Katherine H R Tkaczuk; Yi Qian; Jorge Arellano; C Daniel Mullins; Eberechukwu Onukwugha Journal: PLoS One Date: 2018-03-01 Impact factor: 3.752
Authors: Fränce Hardtstock; Zeki Kocaata; Thomas Wilke; Axel Dittmar; Marco Ghiani; Vasily Belozeroff; David J Harrison; Ulf Maywald; Hans Tesch Journal: Eur J Health Econ Date: 2021-01-18
Authors: Jungho Back; Minh Nam Nguyen; Lu Li; Saelim Lee; Inkyu Lee; Fancheng Chen; Lauren Gillinov; Yeon-Ho Chung; Kareme D Alder; Hyuk-Kwon Kwon; Kristin E Yu; Christopher M Dussik; Zichen Hao; Michael J Flores; Yoseph Kim; Izuchukwu K Ibe; Alana M Munger; Sung Wook Seo; Francis Y Lee Journal: Bone Res Date: 2021-09-29 Impact factor: 13.362
Authors: Leah J McGrath; Robert A Overman; Diane Reams; Karynsa Cetin; Alexander Liede; Steven A Narod; M Alan Brookhart; Rohini K Hernandez Journal: Clin Epidemiol Date: 2018-09-26 Impact factor: 4.790